|
1
|
Tyack ZF, Pegg S and Ziviani J: Postburn
dyspigmentation: Its assessment, management, and relationship to
scarring-a review of the literature. J Burn Care Rehabil.
18:435–440. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gauglitz GG, Korting HC, Pavicic T,
Ruzicka T and Jeschke MG: Hypertrophic scarring and keloids:
Pathomechanisms and current and emerging treatment strategies. Mol
Med. 17:113–125. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aarabi S, Bhatt K A, Shi Y, Paterno J,
Chang EI, Loh SA, Holmes JW, Longaker MT, Yee H and Gurtner GC:
Mechanical load initiates hypertrophic scar formation through
decreased cellular apoptosis. FASEB J. 21:3250–3261. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van der Veer WM, Bloemen MC, Ulrich MM,
Molema G, van Zuijlen PP, Middelkoop E and Niessen FB: Potential
cellular and molecular causes of hypertrophic scar formation.
Burns. 35:15–29. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Younai S, Nichter LS, Wellisz T, Reinisch
J, Nimni ME and Tuan TL: Modulation of collagen synthesis by
transforming growth factor-beta in keloid and hypertrophic scar
fibroblasts. Ann Plast Surg. 33:148–154. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zuccaro J, Ziolkowski N and Fish J: A
systematic review of the effectiveness of laser therapy for
hypertrophic burn scars. Clin Plast Surg. 44:767–779. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li P, He QY and Luo CQ: Overexpression of
miR-200b inhibits the cell proliferation and promotes apoptosis of
human hypertrophic scar fibroblasts in vitro. J Dermatol.
41:903–911. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xiao YY, Fan PJ, Lei SR, Qi M and Yang XH:
MiR-138/peroxisome proliferator-activated receptor β signaling
regulates human hypertrophic scar fibroblast proliferation and
movement in vitro. J Dermatol. 42:485–495. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang X, Zhang Y, Jiang BH, Zhang Q, Zhou
RP, Zhang L and Wang C: Study on the role of Hsa-miR-31-5p in
hypertrophic scar formation and the mechanism. Exp Cell Res.
361:201–209. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen L and Li J, Li Q, Yan H, Zhou B, Gao
Y and Li J: Non-coding RNAs: The new insight on hypertrophic Scar.
J Cell Biochem. 118:1965–1968. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hammond SM: An overview of microRNAs. Adv
Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Soifer HS, Rossi JJ and Saetrom P:
MicroRNAs in disease and potential therapeutic applications. Mol
Ther. 15:2070–2079. 2017. View Article : Google Scholar
|
|
13
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Connell RM, Rao DS, Chaudhuri AA and
Baltimore D: Physiological and pathological roles for microRNAs in
the immune system. Nat Rev Immunol. 10:111–122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang G, Liu Z, Cui G, Wang X and Yang Z:
MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in
breast cancer cells. Tumour Biol. 35:11137–11145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu C, Li M, Hu Y, Shi N, Yu H, Liu H and
Lian H: miR-486-5p attenuates tumor growth and lymphangiogenesis by
targeting neuropilin-2 in colorectal carcinoma. Onco Targets Ther.
9:2865–2871. 2016.PubMed/NCBI
|
|
17
|
Peng Y, Dai Y, Hitchcock C, Yang X, Kassis
ES, Liu L, Luo Z, Sun HL, Cui R, Wei H, et al: Insulin growth
factor signaling is regulated by microRNA-486, an underexpressed
microRNA in lung cancer. Proc Natl Acad Sci USA. 110:15043–15048.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oh HK, Tan AL, Das K, Ooi CH, Deng NT, Tan
IB, Beillard E, Lee J, Ramnarayanan K, Rha SY, et al: Genomic loss
of miR-486 regulates tumor progression and the OLFM4 antiapoptotic
factor in gastric cancer. Clin Cancer Res. 17:2657–2667. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma X, Wei J, Zhang L, Deng D, Liu L, Mei
X, He X and Tian J: miR-486-5p inhibits cell growth of papillary
thyroid carcinoma by targeting fibrillin-1. Biomed Pharmacother.
80:220–226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tredget EE, Nedelec B, Scott PG and
Ghahary A: Hypertrophic scars, keloids, and contractures. The
cellular and molecular basis for therapy. Surg Clin North Am.
77:701–730. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie JL, Qi SH, Pan S, Xu YB, Li TZ, Liu XS
and Liu P: Expression of Smad protein by normal skin fibroblasts
and hypertrophic scar fibroblasts in response to transforming
growth factor beta1. Dermatol Surg. 34:1216–1225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang ZF, Zhang YG, Hu DH, Shi JH, Liu JQ,
Zhao ZT, Wang HT, Bai XZ, Cai WX, Zhu HY and Tang CW: Smad
interacting protein 1 as a regulator of skin fibrosis in
pathological scars. Burns. 37:665–672. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yin L, Zhao X, Ji S, He C, Wang G, Tang C,
Gu S and Yin C: The use of gene activated matrix to mediate
effective SMAD2 gene silencing against hypertrophic scar.
Biomaterials. 35:2488–2498. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu HH, Chen DQ, Wang YN, Feng YL, Cao G,
Vaziri ND and Zhao YY: New insights into TGF-β/Smad signaling in
tissue fibrosis. Chem Biol Interact. 292:76–83. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ji X, Wu B, Fan J, Han R, Luo C, Wang T,
Yang J, Han L, Zhu B, Wei D, et al: The anti-fibrotic effects and
mechanisms of MicroRNA-486-5p in pulmonary fibrosis. Sci Rep.
5:141312015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu B, Sun J, Lei X, Zhu Z, Pei C and Qin
L: MicroRNA-486-5p suppresses TGF-β2-induced proliferation,
invasion and epithelial-mesenchymal transition of lens epithelial
cells by targeting Smad2. J Biosci. 42:575–584. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qi J, Liu Y, Hu K, Zhang Y, Wu Y and Zhang
X: MicroRNA-26a inhibits hyperplastic scar formation by targeting
Smad2. Exp Ther Med. 15:4332–4338. 2018.PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Armour A, Scott PG and Tredget EE:
Cellular and molecular pathology of HTS: Basis for treatment. Wound
Repair Regen. 15 (Suppl 1):S6–S17. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schäfer M and Werner S: Transcriptional
control of wound repair. Annu Rev Cell Dev Biol. 23:69–92. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kwan P, Hori K, Ding J and Tredget EE:
Scar and contracture: Biological principles. Hand Clin. 25:511–528.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Babalola O, Mamalis A, Lev-Tov H and
Jagdeo J: The role of microRNAs in skin fibrosis. Arch Dermatol
Res. 305:763–776. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang Y, Ji C, Guo S, Su X, Zhao X, Zhang
S, Liu G, Qiu X, Zhang Q, Guo H and Chen H: The miR-486-5p plays a
causative role in prostate cancer through negative regulation of
multiple tumor suppressor pathways. Oncotarget. 8:72835–72846.
2017.PubMed/NCBI
|
|
34
|
Fu SJ, Chen J, Ji F, Ju WQ, Zhao Q, Chen
MG, Guo ZY, Wu LW, Ma Y, Wang DP, et al: MiR-486-5p negatively
regulates oncogenic NEK2 in hepatocellular carcinoma. Oncotarget.
8:52948–52959. 2017.PubMed/NCBI
|
|
35
|
Youness RA, El-Tayebi HM, Assal RA, Hosny
K, Esmat G and Abdelaziz AI: MicroRNA-486-5p enhances
hepatocellular carcinoma tumor suppression through repression of
IGF-1R and its downstream mTOR, STAT3 and c-Myc. Oncol Lett.
12:2567–2573. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Viñas JL, Burger D, Zimpelmann J, Haneef
R, Knoll W, Campbell P, Gutsol A, Carter A, Allan DS and Burns KD:
Transfer of microRNA-486-5p from human endothelial colony forming
cell-derived exosomes reduces ischemic kidney injury. Kidney Int.
90:1238–1250. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eppert K, Scherer SW, Ozcelik H, Pirone R,
Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, et
al: MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related
protein that is functionally mutated in colorectal carcinoma. Cell.
86:543–552. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Riggins GJ, Thiagalingam S, Rozenblum E,
Weinstein CL, Kern SE, Hamilton SR, Willson JK, Markowitz SD,
Kinzler KW and Vogelstein B: Mad-related genes in the human. Nat
Genet. 13:347–349. 1996. View Article : Google Scholar : PubMed/NCBI
|
